Diagnostics Market Report Scope & Overview

The Diagnostics Market was valued at USD 312.84 Billion in 2025 and is expected to reach USD 548.62 Billion by 2035, growing at a CAGR of 5.78% from 2026 to 2035.

The global diagnostics market is witnessing high growth due to increasing prevalence of chronic and infectious diseases, increasing adoption of precision medicine, and increasing adoption of advanced laboratory and molecular testing technologies across Roche Diagnostics and Siemens Healthineers have developed AI-powered solutions for molecular diagnostics and diagnostic imaging that met the increasing global demand for accurate healthcare solutions. Next generation sequencing tests, PCR tests, connected diagnostic devices and automated lab solutions will ensure the future growth in the market. In 2025, healthcare diagnostic and laboratory technology solutions witnessed investments of more than USD 390 Billion. Intelligent diagnostic ecosystems have become popular among healthcare providers for disease detection and management.

Roche Diagnostics and Siemens Healthineers have developed AI-powered solutions for molecular diagnostics and diagnostic imaging that met the increasing global demand for accurate healthcare solutions. Next generation sequencing tests, PCR tests, connected diagnostic devices and automated lab solutions will ensure the future growth in the market. In 2025, healthcare diagnostic and laboratory technology solutions witnessed investments of more than USD 390 Billion. Intelligent diagnostic ecosystems have become popular among healthcare providers for disease detection and management.

Market Size and Forecast

• Market Size in 2026E: USD 330.92 Billion
• Market Size by 2035: USD 548.62 Billion
• CAGR: 5.65% from 2026 to 2035
• Fastest Growing Region: Asia Pacific
• Largest Region: North America

Market Trends

• Rising incidence of chronic diseases and infectious diseases is driving the need for advanced molecular diagnostics and early detection of diseases in the world.

• Healthcare providers are more and more adopting AI-enabled imaging systems and automated laboratory workflows for clinical efficiencies and diagnostic accuracy.

• The increasing acceptance of point-of-care testing devices is driving the demand for rapid, portable and real-time diagnostic solutions in hospitals and homecare environments.

• Increasing adoption of next-generation sequencing and biomarker-based diagnostic technologies across the globe due to rising utilisation of precision medicines and personalised treatment approaches.

• The long-term growth of the global diagnostics market is driven by increasing investments in the digital healthcare infrastructure, cloud-connected laboratories and smart diagnostic ecosystems.

U.S. Diagnostics Market Outlook

The U.S. Diagnostics Market was valued at approximately USD 96.42 Billion in 2025 and is expected to reach approximately USD 166.88 Billion by 2035, growing at a CAGR of approximately 5.64% from 2026 to 2035.

U.S. diagnostics industry is experiencing rapid growth driven by high incidence rates of chronic diseases, adoption of precision medicine, and implementation of laboratory and radiology equipment using artificial intelligence technology throughout the country’s healthcare systems. Medical facilities in the nation such as hospitals, labs, and healthcare organizations have started deploying molecular diagnostics, immunodiagnostic tests, next-generation sequencing, and automated clinical test systems in order to enhance disease diagnosis precision and provide personalized therapy for patients. More than 15 billion tests were performed in the year 2025 in the U.S. diagnostics industry.

In March 2025, Thermo Fisher Scientific enhanced the use of advanced molecular diagnostics as well as automated laboratory testing technologies that help in delivering precision health care as well as the management of infectious diseases within the United States. In addition to this, Abbott Laboratories enhanced the use of rapid diagnostics and artificial intelligence-based point-of-care testing solutions for connected healthcare ecosystems in the country. In 2025, the United States made an investment of more than USD 140 billion in healthcare diagnostics and laboratory technology.

Diagnostics Market Segment Analysis

• By Product Type, in vitro diagnostics dominated the diagnostics market with 41.00% share in 2025, while molecular diagnostics are the fastest growing product type with the highest CAGR from 2026 to 2035.

• By Technology, immunoassay dominated the diagnostics market with 36.00% share in 2025, while AI-based diagnostics are the fastest growing technology with the highest CAGR from 2026 to 2035.

• By Application, infectious diseases dominated the diagnostics market with 33.00% share in 2025, while oncology diagnostics are the fastest growing application with the highest CAGR from 2026 to 2035.

• By End User, hospitals dominated the diagnostics market with 44.00% share in 2025, while point-of-care settings are the fastest growing end-user segment with the highest CAGR from 2026 to 2035.

By Product Type, in vitro diagnostics dominate, molecular diagnostics grow fastest

In vitro diagnostics segment dominated the diagnostics market in 2025, with an approximate 41% share of total revenue generated, due to rising demand for laboratory-based disease testing, blood analysis, and infectious disease detection across the globe. Clinical chemistry, immunodiagnostics and automated laboratory testing systems were increasingly adopted by healthcare providers to improve the accuracy of disease diagnosis and support preventive healthcare management. The increasing prevalence of chronic diseases and the increasing healthcare testing infrastructure further accelerated the commercialisation of advanced in vitro diagnostic technologies globally. Worldwide in vitro diagnostic testing volumes exceeded 52 billion tests in 2025, supporting long-term market growth in hospitals and diagnostic laboratories worldwide.

Molecular diagnostics is projected to witness the fastest CAGR over the forecast period owing to the increasing adoption of PCR-based testing, next-generation sequencing, and precision medicine technologies across the globe. The demand for early disease detection and tailored treatment approaches continued to create commercialisation opportunities for advanced molecular diagnostic ecosystems globally.

By Technology, immunoassay dominates, AI-based diagnostics grow fastest

Immunoassay technologies dominated the diagnostics market in 2025, contributing around 36% of the revenue. This dominance is attributed to the growing adoption of these technologies for infectious disease testing, hormone analysis, oncology diagnostics, and chronic disease monitoring worldwide. Hospitals and healthcare facilities worldwide have been increasingly adopting automated immunoassay systems for fast clinical analysis and greater diagnostic accuracy in healthcare laboratories. Growing demand for preventive healthcare screening further supported commercialisation prospects for advanced immunodiagnostic technologies across the globe.

AI-based diagnostics is expected to witness the fastest CAGR owing to the growing adoption of artificial intelligence in imaging diagnostics, pathology workflows and predictive healthcare analytics across the globe. The healthcare providers worldwide have significantly adopted AI-powered clinical decision-support systems and automated disease detection technologies that support faster and more accurate diagnostic outcomes.

By Application, infectious diseases dominate, oncology grows fastest

Infectious diseases dominated the diagnostics market and accounted for around 33% of the total revenue share due to the increasing global testing volumes for viral, bacterial, and respiratory diseases worldwide. The increasing use of rapid molecular testing, immunodiagnostics and PCR based systems in hospitals and diagnostic laboratories is supporting the scale up of infectious disease screening and early diagnosis operations worldwide. Moreover, increasing healthcare surveillance activities and preventive healthcare initiatives further propelled demand for advanced infectious disease diagnostics across the globe. In 2025, testing volumes for infectious diseases worldwide surpassed 24 billion tests, improving commercialisation opportunities for intelligent diagnostic ecosystems globally.

Oncology diagnostics is anticipated to exhibit the fastest CAGR during the forecast period due to the increasing prevalence of cancer and the increasing adoption of precision oncology and biomarker-based testing technologies across the globe. Rising investments in next-generation sequencing and personalised cancer treatment solutions continued to support long term expansion of oncology diagnostic ecosystems globally.

By End User, hospitals dominate, point-of-care settings grow fastest

Hospitals dominated the diagnostics market in 2025 and accounted for around 44% of revenue share owing to increasing patient testing volumes and increasing deployment of integrated laboratory and imaging diagnostic systems across the globe. Automated laboratory platforms, AI-enabled imaging technologies, and advanced molecular testing systems supporting improved disease diagnosis and personalised treatment planning were increasingly adopted by hospitals across healthcare ecosystems worldwide. Rising healthcare infrastructure modernisation activities globally accelerated deployment of advanced diagnostic technologies.

The point-of-care segment is expected to witness the fastest CAGR, driven by the growing demand for quick and portable diagnostic solutions in emergency care, homecare, and outpatient healthcare settings worldwide. The growing use of handheld diagnostic devices and real-time testing technologies continued to spur the commercialisation opportunities for point-of-care diagnostic ecosystems globally.

Regional Analysis

North America Diagnostics Market Insights

The diagnostics market in North America dominated the market in 2025 with a share of 38.4% of the global revenues, due to strong healthcare infrastructure, high volume of diagnostic testing, and rising adoption of precision medicine technologies in the US and Canada. Hospitals and diagnostic laboratories increasingly adopted molecular diagnostics, AI-enabled imaging systems, automated laboratory workflows and next-generation sequencing technologies enabling faster, accurate disease detection. North America diagnostic testing volumes over 22 billion tests in 2025 Thermo Fisher Scientific expanded molecular testing and laboratory automation technologies supporting commercialisation of advanced healthcare diagnostic ecosystems regionally.
The market growth in North America in the long term is being augmented by the rising adoption of AI-powered clinical diagnostics and the growing investments in the digitisation of healthcare. The United States continued to lead in molecular diagnostics and investments in precision healthcare, and Canada accelerated deployment of connected laboratory ecosystems in 2025.

Europe Diagnostics Market Insights

Europe accounted for around 27.2% share of the global diagnostics market revenues which was supported by rising prevalence of chronic disease, robust healthcare reimbursement system and increasing adoption of preventive diagnostics in Germany, France, Italy and United Kingdom. Regionally, the healthcare providers increasingly adopted immunodiagnostics, molecular testing platforms and AI-enabled imaging systems that support early disease detection and precision healthcare management. In 2025 Europe's healthcare diagnostic spending surpassed USD 118 Billion with Siemens Healthineers supporting the commercialisation of sophisticated diagnostic ecosystems across the region by reinforcing AI-enabled imaging and automated laboratory technologies.

Long-term market growth across Europe is driven by increasing investments in cancer diagnostics and rising adoption of precision medicine technologies. Germany continued to be the leader in advanced laboratory diagnostics in 2025, while the UK was building digital pathology and AI-enabled healthcare diagnostic ecosystems.

Asia Pacific Diagnostics Market Insights

Asia Pacific is estimated to account for around 25.8% of the global diagnostics market revenues, owing to an expanding healthcare infrastructure, increasing healthcare awareness, and rising deployment of molecular and point-of-care diagnostic technologies in China, Japan, India, and South Korea. Governments and healthcare providers invested heavily in automated laboratories, infectious disease diagnostics and ecosystems of precision medicine that facilitated large scale disease screening and preventive healthcare management. Asia Pacific diagnostic testing volumes exceeded 26 billion tests in 2025. Sysmex Corporation expanded automated haematology and intelligent laboratory diagnostic technologies to enable commercialisation of advanced healthcare testing ecosystems within the region.

Increasing digitisation of healthcare and rising investments in affordable diagnostic technologies are fuelling long-term market expansion across Asia Pacific. In 2025, India will accelerate adoption of point-of-care diagnostics and digital healthcare ecosystems, while China will continue to lead in infectious disease testing and laboratory automation.

Middle East & Africa & Latin America Diagnostics Market Insights

The Middle East & Africa and Latin America together contributed to nearly 8.6% of the global diagnostics market revenues in 2025, driven by the growing healthcare modernisation activities, increasing infectious disease testing volumes, and rising investments in clinical laboratory infrastructure in Brazil, Saudi Arabia, UAE, South Africa, and Argentina. Regionally, healthcare providers increasingly adopted rapid diagnostic testing, portable molecular diagnostics, and automated laboratory technologies supporting improved disease detection and preventive healthcare management. Abbott Laboratories amplified adoption of rapid testing and point-of-care diagnostic technologies in support of global commercialised advanced healthcare diagnostic ecosystems while regional healthcare diagnostic spending surpassed USD 42 Billion during 2025.

Brazil retained its leadership in regional laboratory testing infrastructure, while Saudi Arabia accelerated healthcare digitisation and molecular diagnostic investments during 2025. The continued increasing adoption of rapid testing technologies and portable diagnostic solutions supported the long-term expansion of healthcare diagnostic ecosystems across emerging regional markets globally.

Market Dynamics

Growth Drivers: Rising chronic disease burden and precision diagnostics adoption

The increase in the prevalence of chronic and infectious diseases and increased usage of precision medicine technology is driving growth for the global diagnostic market substantially. The growing trend of using molecular diagnostics, imaging systems based on artificial intelligence, immunodiagnostic tests, and next-generation sequencing tests is helping detect diseases and develop treatment plans tailored for patients across the globe. Increasing need for preventive healthcare screening and clinical diagnostics is contributing to an increase in investment in healthcare technology that facilitates advanced healthcare testing processes around the world. Testing volumes in the field of diagnostics surpassed 78 billion tests in 2025 globally.

Restraints: High diagnostic equipment costs and regulatory complexity

Expensive installations of cutting-edge diagnostic solutions and rising compliance obligations have become major issues for global diagnostics companies. Molecular tests, automation of laboratory processes and artificial intelligence-driven imagery all come with great costs in infrastructure, software and competent health care experts. Moreover, the compliance requirements related to clinical testing, patient privacy and diagnostic accuracy have further complicated operations for the health care facilities across the globe. Overall, the global health care sector has seen a rise of over 9% in costs for laboratory equipment in 2025.

Opportunities: Expansion of AI-enabled diagnostics and point-of-care testing

Increasing adoption of AI-powered diagnostic technologies and increasing deployment of portable point-of-care testing systems are creating significant commercialisation opportunities across the global diagnostics market. Healthcare providers around the world are increasingly adopting cloud-connected laboratory systems, AI-enabled pathology platforms, wearable diagnostic technologies and rapid molecular testing solutions to support faster clinical decision-making and decentralised healthcare delivery. Increasing investments in telehealth and digital healthcare ecosystems are also driving the long-term growth opportunities of intelligent diagnostics technologies globally. Global digital healthcare and AI-diagnostics investments surpassed USD 160 Billion in 2025. Increasing demand for rapid and personalised testing solutions drove the commercialisation of next-generation diagnostic ecosystems across the globe.

Recent Developments

• In March 2025, Roche Diagnostics enhanced their capabilities in AI-assisted molecular testing and automation in lab workflows related to precision healthcare and management of infectious diseases.

• In February 2025, Siemens Healthineers advanced their offerings of AI-assisted imaging diagnostics and cloud-enabled radiology solutions related to advanced clinical decision-support systems.

• In January 2025, Abbott Laboratories advanced their rapid POCT solutions and portable molecular diagnostics for the global healthcare sector.

• In January 2025, Thermo Fisher Scientific advanced next-generation sequencing and oncology diagnostics to support precision medicine worldwide.

• In January 2025, Sysmex Corporation advanced its offerings of intelligent hematology and automated clinical laboratory systems for high-throughput healthcare testing ecosystems

.Key Players

• Roche Diagnostics

• Siemens Healthineers

• Abbott Laboratories

• Thermo Fisher Scientific

• Danaher Corporation.

• Becton Dickinson and Company

• Sysmex Corporation

• Bio-Rad Laboratories

• Quest Diagnostics

• Qiagen N.V.

• Hologic Inc

• Illumina Inc

• bioMérieux S.A.,

• GE HealthCare

• Koninklijke Philips N.V.

• Agilent Technologies

• PerkinElmer Inc.

• Mindray Medical International

• NeoGenomics Laboratories

• Exact Sciences Corporation

Diagnostics Market Report Scope: